UNDERSTANDING THE CLOSTRIDIUM SPORE, A PREREQUISTE FOR DISEASE INTERVENTIONS AND EXPLOITATION

Project Information

CLOSPORE

Grant agreement ID: 642068

DOI 10.3030/642068

Project closed

EC signature date 16 December 2014

Start date 1 January 2015

End date 31 December 2018

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost € 3 910 777,56

EU contribution € 3 910 777,56

Coordinated by

THE UNIVERSITY OF NOTTINGHAM
United Kingdom

Deliverables

Other (20)

Sporulation Mutants Isolated

Directed random from Clostridium sp

Germination Mutants Isolated

Directed random from Clostridium sp

Increased understanding of disease

Improved epidemiology/ diagnostics

Characterised sporulation genes

Role of sporulation genes determined

ESRs recruited

Target date for all starters

First ESR scientific presentation

Given at nationalinternational meeting

Appointment of Supervisory Board

Supervisory Board committee members selected

Conditionally CDEPTsporulating strain

Prototype strain for clinical trial

Decision-making at single cell level

Understanding sporulationtoxigenesis

Ethics

Delivery of ethics documents before commencement of the relevant part of the research

Exemplification of ACE technology

Demonstrated in target Clostridium sp

Characterised germination genes

Role of germination genes determined

Promotional material distributed

Webdownloads and meeting flyers

Mid-term Conference

Conference Proceedings at website

Submission of Doctorate Thesis

Subject to National requirements

Universal transposon exemplified

Exemplified in target Clostridium

Final Conference Proceedings

Conference Proceedings at website

Spore regulators common to toxins

Links to toxin/metabolite production

New sporulation/germination genes

In pathogenic nonpathogenic clostridia

Asporogenous butanol producers

In C acetobutylicum Clostridium sp

Documents, reports (1)

Final Report

Final Project report submitted to commission

Websites, patent fillings, videos etc. (2)

Social Media Established

Twitter account Facebook Page active

CLOSPORE website

Website established at wwwclosporenet

Publications

Peer reviewed articles (5)

Hijacking CRISPR-Cas for high-throughput bacterial metabolic engineering: advances and prospects

Author(s): Ioannis Mougiakos, Elleke F Bosma, Joyshree Ganguly, John van der Oost, Richard van Kranenburg
Published in: Current Opinion in Biotechnology, Issue 50, 2018, Page(s) 146-157, ISSN 0958-1669
Publisher: Elsevier BV
DOI: 10.1016/j.copbio.2018.01.002

Investigating the Central Metabolism of Clostridium thermosuccinogenes

Author(s): Jeroen Girwar Koendjbiharie, Kilian Wiersma, Richard van Kranenburg
Published in: Applied and Environmental Microbiology, Issue 84/13, 2018, Page(s) e00363-18, ISSN 0099-2240
Publisher: American Society for Microbiology
DOI: 10.1128/AEM.00363-18

L-Rhamnose metabolism in Clostridium beijerinckii DSM 6423

Author(s): M. Diallo, A. D. Simons, H. van der Wal, F. Collas, Bwee Houweling-Tan, S. W. M. Kengen, A. M. López-Contreras
Published in: Applied and Environmental Microbiology, 2018, ISSN 0099-2240
Publisher: American Society for Microbiology
DOI: 10.1128/aem.02656-18

Generation of a fully erythromycin-sensitive strain of Clostridioides difficile using a novel CRISPR-Cas9 genome editing system

Author(s): Patrick Ingle, Daphne Groothuis, Peter Rowe, He Huang, Alan Cockayne, Sarah A. Kuehne, Weihong Jiang, Yang Gu, Christopher M. Humphreys, Nigel P. Minton
Published in: Scientific Reports, Issue 9/1, 2019, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-019-44458-y

RiboCas: A Universal CRISPR-Based Editing Tool for Clostridium

Author(s): Inés C. Cañadas, Daphne Groothuis, Maria Zygouropoulou, Raquel Rodrigues, Nigel P. Minton
Published in: ACS Synthetic Biology, 2019, ISSN 2161-5063
Publisher: American Chemical Society
DOI: 10.1021/acssynbio.9b00075

Intellectual Property Rights

Patent (1)

PROCESSES INVOLVING CLOSTRIDIUM SACCHAROPERBUTYLACETONICUM

Application/Publication number: PCT/ GB2018/052937
Date: 2018-10-12
Applicant(s): BIOCLEAVE LIMITED